Generic Name: osimertinib
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations.It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Osimertinib was approved for medical use in the United States in November 2015,and in the European Union in February 2016.
What is Tagrisso?
Tagrisso (osimertinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Tagrisso is used to treat a certain type of non-small cell lung cancer. Osimertinib is used only if your tumor has a specific genetic marker, for which your doctor will test.
Tagrisso is usually given after other treatments have failed.
Tagrisso may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking this medicine and during treatment. Call your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded.
Before taking this medicine
You should not use Tagrisso if you are allergic to osimertinib.
To make sure Tagrisso is safe for you, tell your doctor if you have ever had:
a breathing disorder;
an electrolyte imbalance (such as high or low levels of calcium, potassium, or magnesium in your blood);
long QT syndrome (in you or a family member).
Osimertinib can harm an unborn baby if the mother or the father is using this medicine.
If you are a woman, do not use Tagrisso if you are pregnant. You may need to have a negative pregnancy test before starting this treatment. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 6 weeks after your last dose.
If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 4 months after your last dose.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using Tagrisso.
This medicine may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because osimertinib can harm an unborn baby.
You should not breast-feed while using this medicine and for at least 2 weeks after your last dose.